What is the role of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in the scenario of new drugs for Multiple Myeloma (MM)

Authors

  • Abrahão Elias Hallack Neto Department of Internal Medicine, University Hospital, Universidade Federal de Juiz de Fora (UFJF), Juiz de Fora, Minas Gerais, Brazil
  • Angelo Maiolino Department of Internal Medicine, University Hospital, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; Américas Centro de Oncologia Integrado - Title summarized: AHSCT and new drugs for MM

DOI:

https://doi.org/10.46765/2675-374X.2020v1n1p27-29

Abstract

Patients with multiple myeloma (MM) in clinical con­ditions to be referred to autologous hematopoietic stem cell transplantation (AHSCT) generally start therapy with an induction chemotherapy followed by high-dose alkylating and AHSCT. The ideal regimen and the number of pre-AHSCT induction is still a controversial subject, however, opting for at least three to four cycles of chemotherapy including a drug with immunomodulatory action, a protea­some inhibitor, with a corticosteroid, are advised as the first line before AHSCT.

Downloads

Published

07/06/2020

How to Cite

Hallack Neto, A. E., & Maiolino, A. (2020). What is the role of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in the scenario of new drugs for Multiple Myeloma (MM). JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(2), 27–29. https://doi.org/10.46765/2675-374X.2020v1n1p27-29

Issue

Vol. 1 No. 2 (2020): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

Most read articles by the same author(s)